Philidor

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have appreciated 17.21 percent over the past three months, while declining 0.35 percent over the past month. Rodman & Renshaw’s Raghuram Selvaraju has initiated coverage of the company with a Buy rating and price target of $150...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have lost around 55 percent since peaking at $264 back in August. Joshua Schimmer of Piper Jaffray suggested that Valeant could break up its corporate structure in 2016. The analyst suggested that many large investors might begin thinking the...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) recently held its Investor Day, where management provided revised guidance, in line with estimates. Following the event, CIBC analysts Prakash Gowd and Ryan Lee issued a Sector Perform rating and $90 price target on the shares. The experts commented...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) stock surged to 12.50 percent to $109.80 in Tuesday's afternoon trading session, following its new 20-year deal announcement to cut prices for Walgreens Boots Alliance Inc (NASDAQ: WBA). The drug deal comes six weeks after the company had cut ties with...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has fought back recently against accusations of spiking inventory levels. A build in inventory levels could ultimately result in production or pricing cuts. A new investigation into Valeant’s operations in Poland reveals some potentially troubling...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) are now lower by 70 percent over the past three months. Analysts at Deutsche Bank and Morgan Stanley both raised concerns on the company's business. Gregg Gilbert of Deutsche Bank noted a propriety survey with doctors indicated...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are down 70 percent in the past three months as allegations of accounting fraud continue to swirl. Many companies involved in accounting fraud eventually end up bankrupt. However, some companies find ways to weather the storm in the long run....

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are relatively unchanged in Tuesday's after-hours session following a press release from Philidor. The specialty pharma company said it's "deeply disappointed" its working relationship with Valeant has ended, adding that it...

Bill Ackman is not bailing on his Valeant Pharmaceuticals Intl Inc (NYSE: VRX) investment anytime soon. In his quarterly call to investors, Ackman expressed his confidence in the long-term future of the company. Pershing Square is down about 19 percent in 2015. Bill Ackman stood firm...

Citron Research's executive editor Andrew Left appeared on CNBC on Monday, talking about Valeant Pharmaceuticals Intl Inc (NYSE: VRX). "Valeant calls your accusations – in their words ‘sensational, false and misleading, like yelling fire in a crowded in a crowded...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were higher by 6 percent late Monday morning. Notable short-seller Citron Research said that it will not "dial back warnings" on Valeant. Citron said that it also "stands by" its Enron analogy and that Valeant has...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have declined 47.79 percent over the past month, hitting a low of $90.51 on October 21. Goldman Sachs’ Gary Nachman has downgraded the rating on the company from Buy to Neutral, while lowering the price target from $180 to $122. Nachman...

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has announced it is cutting ties with Philidor RX Services. Valeant’s stock is down 6 percent on the news. Analysts are downplaying the impact that the decision will ultimately have on Valeant. Valeant shares are down 6 percent in...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have declined 56.31 percent over the last three months, hitting a low of $109.54 on October 27. Sumant S. Kulkarni of Bank of America Merrill Lynch has maintained a Buy rating on the company, with a price target of $173. Kulkarni...

The buzz phrase "specialty pharmacies" -- much like "drug pricing" a few weeks ago -- spread through the biotech world as Citron Research came out Wednesday with a short thesis on Valeant Pharmaceuticals Intl Inc (NASDAQ: VRX). Using investigative research obtained by Southern...